About lumasiran (ALN-GO1), an investigational medicine for PH1

Lumasiran (pronounced “lu-MAH-si-ran”, and formerly called ALN-GO1) is an investigational medication that may reduce or prevent the overproduction of oxalate in people with PH1. Alnylam’s program of clinical research studies, including the ILLUMINATE clinical trials, will determine if it can safely and effectively reduce the liver’s oxalate production in people with PH1.